Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Joe Y. Chang*, Suresh Senan, Marinus A. Paul, Reza J. Mehran, Alexander V. Louie, Peter Balter, Harry J. M. Groen, Stephen E. McRae, Joachim Widder, Lei Feng, Ben E. E. M. van den Borne, Mark F. Munsell, Coen Hurkmans, Donald A. Berry, Erik van Werkhoven, John J. Kresl, Anne-Marie Dingemans, Omar Dawood, Cornelis J. A. Haasbeek, Larry S. CarpenterKatrien De Jaeger, Ritsuko Komaki, Ben J. Slotman, Egbert F. Smit, Jack A. Roth

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

879 Citations (Web of Science)

Abstract

Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stage I NSCLC (STARS and ROSEL) closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these trials. Methods Eligible patients in the STARS and ROSEL studies were those with clinical T1-2a (
Original languageEnglish
Pages (from-to)630-637
JournalLancet oncology
Volume16
Issue number6
DOIs
Publication statusPublished - Jun 2015

Cite this